PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

Robert Seifert1,2,3,4 · Katharina Kessel1 · Katrin Schlack3,5 · Manuel Weber2,3,4 · Ken Herrmann2,3,4 · Maximilian Spanke2,3,4 · Wolfgang P. Fendler2,3,4 · Boris Hadaschik3,4,6 · Jens Kleesiek4,7 · Michael Schäfers1,3 · Matthias Weckesser1,3 · Martin Boegemann3,5 · Kambiz Rahbar1,3 · Michael Schäfers1,3 · Kambiz Rahbar1,3

Abstract

Introduction [177Lu]Lu-PSMA-617 (Lu-PSMA) radioligand therapy is an emerging treatment option for patients with end-stage prostate cancer. However, response to Lu-PSMA therapy is only achieved in approximately half of patients. It is clinically important to identify patients at risk of poor outcome. Therefore, the aim of this study was to evaluate pretherapeutic PSMA PET derived total tumor volume and related metrics as prognosticators of overall survival in patients receiving Lu-PSMA therapy.

Methods A total number of 110 patients form the Departments of Nuclear Medicine Münster and Essen were included in this retrospective analysis. Baseline PSMA PET-CT was available for all patients. Employing a previously published approach, all tumor lesions were semi-automatically delineated in PSMA PET-CT acquisitions. Total lesion number, total tumor volume (PSMA-TV), total lesion uptake (PSMA-TLU = PSMA-TV * SUVmean), and total lesion quotient (PSMA-TLQ = PSMA-TV / SUVmean) were quantified for each patient. Log2 transformation was used for regressions.

Results Lesion number, PSMA-TV, and PSMA-TLQ were prognosticators of overall survival (HR = 1.255, \( p = 0.009 \); HR = 1.299, \( p = 0.005 \); HR = 1.326, \( p = 0.002 \)). In a stepwise backward Cox regression including lesion number, PSMA-TV, PSA, LDH, and PSMA-TLQ, only the latter two remained independent and statistically significant negative prognosticators of overall survival (HR = 1.632, \( p = 0.011 \); HR = 1.239, \( p = 0.024 \)). PSMA-TLQ and LDH were significant negative prognosticators in multivariate Cox regression in contrast to PSA value.

Conclusion PSMA-TV was a statistically significant negative prognosticator of overall survival in patients receiving Lu-PSMA therapy. PSMA-TLQ was an independent and superior prognosticator of overall survival compared with PSMA-TV.

Keywords PSMA · PET-CT · Total tumor volume · Lu-PSMA · mCRPC

Introduction

The management of end-stage metastatic prostate cancer is challenging, as only limited therapeutic options are present [1]. However, [177Lu] Lutetium PSMA-617 (Lu-PSMA) radioligand therapy has become a promising treatment option in end-stage prostate cancer and is currently employed after failure of androgen deprivation therapy, next generation androgen receptor targeted therapy (ARTA), and taxane chemotherapy [2, 3]. It offers a favorable tolerability, and the efficacy is currently evaluated in prospective trials, including a head-to-head comparison against cabazitaxel [4–7].

Biochemical response (PSA decline by at least 50% from baseline) of patients undergoing Lu-PSMA therapy is achieved in 45–66% of cases [2, 3, 8]. Therefore, the
identification of biomarkers that are associated with response to Lu-PSMA therapy and outcome is of great importance, as this would enable early management changes.

It is well known that a high volume of disease is a negative prognostic factor of patients with prostate cancer [9, 10]. For example, the volumetric bone scan index, which is measuring the volumetric affection of the skeleton by metastases, was an excellent prognosticator of overall survival in prostate cancer patients [11]. As Lu-PSMA therapy is applied in fixed doses and not in a disease extent adapted fashion, the tumor volume could be even more predictive of overall survival. However, there are contradictory reports on the prognostic value of the total tumor volume for patients treated by Lu-PSMA therapy: Ferdinandus et al. had not observed a statistically significant correlation between PSMA-TV and overall survival in 50 patients treated with Lu-PSMA [12]. Yet, a preliminary analysis by Seifert et al. found PSMA-TV to be significantly correlated with the overall survival in patients treated with Lu-PSMA [13].

It might be of clinical importance to evaluate the prognostic value of PSMA-TV for Lu-PSMA patients, as PSMA-TV could potentially be employed to anticipate the need of therapy intensification. Therefore, the aim of this study was to evaluate if PSMA PET derived tumor volume parameters could prognosticate the overall survival of patients treated with Lu-PSMA therapy. To this end, patients from two departments, which had partly been included in previous analyses, were included to specifically evaluate the relevance of the total tumor volume and related parameters.

**Methods**

**Patients and eligibility for [¹⁷⁷Lu]Lu-PSMA-617 therapy**

All patients referred to Lu-PSMA therapy in either Essen or Münster between December 2014 and November 2018 who underwent baseline PSMA-11 PET-CT prior to Lu-PSMA therapy were included in this retrospective analysis. Patients were eligible for therapy, if they met the following inclusion criteria: progressive, metastatic castration-resistant prostate cancer (mCRPC), history of chemotherapy (docetaxel or cabazitaxel) if no contraindications were present, PSMA avid tumor lesions, adequate hematological reserve and adequate liver, as well as renal function parameters [14].

Decision for Lu-PSMA therapy was done on a case-by-case basis in the interdisciplinary tumor boards due to clinical indication. Data analysis was done retrospectively. The retrospective analysis of the Münster cohort was approved by the local ethics committee (No. 19-8570-BO). The Münster cohort was previously employed for an analysis of SUV metrics [15]. The previously reported patient cohort (n = 40) that was used for a preliminary technical analysis is also included in this study [13]. Patients from Essen have been reported previously in a study investigating diffuse bone marrow involvement [16].

**Administration of [¹⁷⁷Lu] Lutetium PSMA-617 therapy**

The PSMA-617 precursor was provided by ABX (ABX GmbH, Radeberg, Germany). [¹⁷⁷Lu] Lutetium was provided by ITG Isotopes Technology, Garching, Germany. Syntheses of [¹⁷⁷Lu]Lu-PSMA-617 (Lu-PSMA) was done as described elsewhere [17]. Lu-PSMA was administered every 8 weeks (median 8.0 weeks [2.6]) in a medium dose of 6.7 GBq [12] until disease progression, severe adverse reactions, altered therapy regime, or death.

**PSMA PET imaging**

The PSMA-11 precursor was obtained from ABX (ABX GmbH, Radeberg, Germany). Image acquisition was initiated 60 min after tracer administration. A Biograph mCT was used for image acquisition (Siemens Healthineers, Knoxville, TN, USA). Median time from PET acquisition until Lu-PSMA therapy start was 32 days [18]. PET reconstruction was done using manufacture standard tools (with iterative reconstruction and time of flight correction, but without point spread function adjustments).

**PET image analysis**

A research software prototype was used for image analysis (MIWBAS, version 1.0, Siemens Medical Solutions USA, Inc., Knoxville, TN, USA). Semi-automated PSMA PET lesion delineation was done as described elsewhere [13]. For segmentation, a liver specific threshold was employed: threshold = (4.3 / liver $SUV_{\text{mean}}$) * (liver $SUV_{\text{mean}}$ + liver $SUV_{\text{standard deviation}}$). Briefly, all metastases with an $SUV_{\text{peak}}$ greater than the liver specific threshold were segmented. Delineable lesions with PSMA uptake lesser than the liver specific threshold were manually added, if necessary (in 7 patients). Lesions smaller than 0.5 ml were discarded.

Segmentation of each individual lesion was done by calculating a lesion specific threshold, which was defined as 50% of the maximum local SUV. The volume of a segmented lesion was denoted TV. The volumes of all lesions are summed to obtain the whole-body PSMA-TV for each patient (Eq. 1) [13]:

$$PSMA-TV = \sum_{\text{lesions}} TV$$ (1)
In analogy to FDG total lesion glycolysis, the TV of each lesion was multiplied by its $SUV_{\text{mean}}$. The resulting products are summed to obtain the whole-body PSMA-TLU for each patient (Eq. 2) [19]:

$$PSMA-\text{T Lu} = \sum_{\text{lesions}} TV \times SUV_{\text{mean}}$$ (2)

PSMA-TV is suspected to be a negative prognosticator of survival, whereas $SUV_{\text{mean}}$ is suspected to be a positive prognosticator; both effects may antagonize in the PSMA-TLU biomarker [12, 13]. Therefore, the TV of each lesion was divided by its $SUV_{\text{mean}}$. The resulting quotients are summed to obtain the whole-body PSMA-TLQ for each patient (Eq. 3):

$$PSMA-\text{T LQ} = \sum_{\text{lesions}} \frac{TV}{SUV_{\text{mean}}}$$ (3)

**Statistical analysis**

SPSS version 25 was used for descriptive statistics, univariate and multivariate (Cox-) regression, spearman correlation, and Mann Whitney U tests (IBM Corp., Armonk, NY, USA). For stepwise Cox regression, a backward LR approach with standard settings of SPSS was employed. Logarithmic transformation (base 2, log transformed) was used for regression analyses. R version 3.5.2 was used to find ideal cutoffs for survival stratification, log rank tests, and Kaplan Meier curves [20, 21]. The log-log option was used to calculate the confidence intervals for overall survival time. Values are presented as median with inter quartile range in squared brackets. $H_0$ was rejected if $p < 0.05$.

**Results**

**Patient characteristics**

All patients were castration resistant and received androgen deprivation therapy; 97.3% had received prior next generation antiandrogen treatment (enzalutamide and/or abiraterone). Eighty-one percent of patients had a history of docetaxel treatment (26% of cabazitaxel treatment). Detailed patient characteristics are given by Table 1.

**Correlation of non-image parameters and PSMA PET derived parameters**

Lesion number ($\rho = 0.589, p < 0.001$), PSMA-TV ($\rho = 0.617, p < 0.001$), PSMA-TLU ($\rho = 0.525, p < 0.001$), and PSMA-TLQ ($\rho = 0.608, p < 0.001$) showed statistically significant correlations with prostate-specific antigen (PSA) levels.

**Correlations with lactate dehydrogenase were not as strong as correlations with PSA levels (Table 2).**

| Parameter                  | Prostate-specific antigen | Lactate dehydrogenase |
|----------------------------|---------------------------|------------------------|
| Lesion number              | 0.589; $P < 0.001$        | 0.317; $P = 0.001$     |
| PSMA-TV                    | 0.617; $P < 0.001$        | 0.363; $P < 0.001$     |
| PSMA-TLU                   | 0.525; $P < 0.001$        | 0.230; $P = 0.016$     |
| PSMA-TLQ                   | 0.608; $P < 0.001$        | 0.396; $P < 0.001$     |

Spearman correlations are shown. PSMA-TV PSMA tumor volume, $PSMA-\text{T LU}$ PSMA tumor volume multiplied by $SUV_{\text{mean}}$, $PSMA-\text{T LQ}$ PSMA tumor volume divided by $SUV_{\text{mean}}$. 

---

Table 1  Patient characteristics

| Patient characteristics | Total cohort |
|-------------------------|-------------|
| Number of patients      | 110         |
| Patients from Essen/Münster | 25/85     |
| Age                     | 72 [11.1]  |
| Gleason score           | 8 (range: 5–10) |
| Metastases locations    |             |
| Bone                    | 102 (92.7%)|
| Lymph nodes             | 84 (76%)   |
| Liver                   | 26 (24%)   |
| Lung/pleura             | 24 (22%)   |
| History of previous therapies |         |
| Abiraterone             | 92 [83.6%] |
| Enzalutamide            | 90 [81.8%] |
| Docetaxel               | 92 [80.9%] |
| Cabazitaxel             | 29 [26.4%] |
| Pre- Lu-PSMA therapy blood parameter |       |
| Prostate-specific antigen [ng/ml] | 231.0 [587.5] |
| Lactate dehydrogenase [U/l] | 317.0 [245.0] |
| Aspartate aminotransferase [U/l] | 33.0 [24.0]  |
| Alanine transaminase [U/l] | 19.0 [34.0]  |
| White blood cell count [/μl] | 6.0 [2.7]    |
| Hemoglobin [g/dl]        | 10.5 [2.6]  |
| Platelets [/μl]          | 234.0 [117.0] |
| Lu-PSMA therapy          |             |
| Number of Lu-PSMA cycles | 3 (range: 1–12) |
| Time between PSMA PET and Lu-PSMA start [days] | 32 [22]  |
| Average activity per cycle [GBq] | 6.7 [1.2]    |
| Cumulated activity [GBq] | 21.2 [18.9] |

Values are presented as median (inter quartile range) or frequency (percentage of all patients); $PSMA$ prostate-specific membrane antigen, $Lu-PSMA$ $^{177}$Lu-PSMA-617 therapy

---

* Springer
PSMA PET derived parameters and overall survival

Log transformed number of lesions was a statistically significant prognosticator of overall survival in univariate Cox regression ($p = 0.009$; HR = 1.255; 95%CI = 1.058–1.488). The same was true for PSMA-TV ($p = 0.005$; HR = 1.299; 95%CI = 1.081–1.561), PSMA-TLU ($p = 0.046$; HR = 1.171; 95%CI = 1.003–1.367), and PSMA-TLQ ($p = 0.002$; HR = 1.326; 95%CI = 1.112–1.580).

In a stepwise backward Cox regression including log transformed PSMA-TV and lesion number, only PSMA-TV remained as significant parameter ($p = 0.005$; HR = 1.299; 95%CI = 1.081–1.561). In a stepwise backward Cox regression including log transformed PSMA-TV, lesion number, prostate-specific antigen, lactate dehydrogenase, and PSMA-TLQ, only the latter two remained significant parameters in the model (LDH ($p = 0.011$; HR = 1.632; 95%CI = 1.120–2.376), PSMA-TLQ ($p = 0.024$; HR = 1.239; 95%CI = 1.029–1.492)). Multivariate Cox regression including log transformed prostate-specific antigen, lactate dehydrogenase, and PSMA-TLQ confirmed the latter two to be significant prognosticators of survival (LDH ($p = 0.013$; HR = 1.638; 95%CI = 1.110–2.418), PSMA-TLQ ($p = 0.043$; HR = 1.244; 95%CI = 1.007–1.538)). Detailed results are shown in Table 3.

Binarized PSMA PET derived parameters and overall survival

Median overall survival of patients was significantly different between lesion number quartile 1 and quartile 4 ($p = 0.02$; 23.5 [95%CI: 11.0–NR] months vs. 8.6 [95%CI: 5.0–15.1] months), NR denotes not determinable values due to not reached median survival time. The same was true for quartiles 1 and 4 of PSMA-TV ($p = 0.002$; 21.3 [95%CI: 7.87–NR] months vs. 7.5 [95%CI: 5.0–9.9] months) and quartiles 1 and 4 of PSMA-TLQ ($p < 0.001$; 23.5 [95%CI: 12.9–NR] months vs. 7.5 [95%CI: 4.5–15.1] months). Median OS of quartiles 1 and 4 of PSMA-TLU were not statistically significant different from each other ($p = 0.17$; 14.2 [95%CI: 7.0–NR] months vs. 8.6 [95%CI: 6.5–NR] months). Figures 1 and 2 display the survival of stratified by the quartiles of PSMA-TV, PSMA-TLU, PSMA-TLQ, LDH, and PSA. Median overall survival of patients in PSMA-TLQ quintile 1 (21.5 [95%CI: 12.9–NR] months), quintiles 2–4 (11.4 [95%CI: 8.6–14.8] months), and quintile 5 (5.3 [95%CI: 3.6–9.9] months) were significantly different from each other (global ($p < 0.001$), quintile 1 vs. 4 ($p < 0.001$), quintiles 2–4 vs. 5 ($p = 0.0042$), quintiles 2–4 vs. 1 (0.040)). Figure 3 displays the stratification of PSMA-TV and PSMA-TLQ side by side.

Ideal log rank cutoffs were determined for PSMA-TLQ (cutoff: 514; $p = 0.011$; 23.5 vs. 9.9 months), prostate-specific antigen (cutoff: 514; $p = 0.011$; 14.8 vs. 7.2 months), and other parameters (see Table 4). Figure 4 displays the Kaplan Meier curves according to ideal log rank cutoffs.

Comparison of the Münster and Essen cohort

There was no statistically significant difference regarding overall survival between the Münster and the Essen cohort (11.8 vs. 11.0 months, $p = 0.96$; HR = 0.984; 95%CI = 0.542–1.785; $p = 0.957$; see Fig. 4). Comparing the Münster and Essen cohort, the cumulated Lu-PSMA activity (19.3 vs. 22.2; $p = 0.853$), lactate dehydrogenase (316.5 vs. 317.0; $p = 0.332$), and prostate-specific antigen (284.0 vs. 145.0; $p = 0.254$) were not significantly different (see Fig. 5).

Tumor volume and metastases location

PSMA-TV was a statistically significant negative prognosticator (HR = 1.236; 95%CI = 1.025–1.490; $p = 0.027$) in a multivariate Cox regression adjusted for presence of visceral

| Parameter                  | Univariate Cox regression | Multivariate Cox regression |
|----------------------------|---------------------------|-----------------------------|
|                            | HR [95%CI]                | P                           |
| Lesion number              | 1.255 [1.058–1.488]       | 0.009                       |
| PSMA-TV                    | 1.299 [1.081–1.561]       | 0.005                       |
| PSMA-TLU                   | 1.171 [1.003–1.367]       | 0.046                       |
| PSMA-TLQ                   | 1.326 [1.112–1.580]       | 0.002                       |
| Prostate-specific antigen   | 1.147 [1.021–1.289]       | 0.021                       |
| Lactate dehydrogenase      | 1.901 [1.347–2.685]       | < 0.001                     |

All included parameters were log (base2) transformed. HR hazard ratio, CI confidence interval, PSMA-TV PSMA tumor volume, PSMA-TLU PSMA tumor volume multiplied by $SUV_{mean}$, PSMA-TLQ PSMA tumor volume divided by $SUV_{mean}$.
(liver, lung, and/or pleura) (HR = 1.630; 95%CI = 0.950–2.795; p = 0.076), lymph node (HR = 1.060; 95%CI = 0.543–2.068; p = 0.865), or bone metastases (HR = 1.726; 95%CI = 0.587–5.071; p = 0.321). Likewise, PSMA-TLQ was a statistically significant negative prognosticator (HR = 1.278; 95%CI = 1.064–1.535; p = 0.009) in a multivariate Cox regression adjusted for the presence of visceral (liver, lung, and/or pleura) (HR = 1.640; 95%CI = 0.959–2.803; p = 0.071), lymph node (HR = 1.153; 95%CI = 0.590–2.253; p = 0.678), or bone metastases (HR = 1.601; 95%CI = 0.540–4.747; p = 0.396).

Discussion

The present study evaluated PSMA tumor volume as biomarker to prognosticate the outcome of patients with mCRPC who were receiving Lu-PSMA therapy. To this end, the total tumor volume and related parameters were quantified in the baseline PSMA PET-CT acquisition prior to the first administration of Lu-PSMA therapy. The total tumor volume was a statistically significant negative prognosticator of survival. The integration of SUV and total tumor volume (PSMA-TLQ) leads to an improved stratification of patients according to outcome. Finally, PSMA-TLQ remained an independent prognosticator of survival in a multivariate regression including LDH and PSA blood levels.

It was shown previously that the total osseous tumor volume of patients with prostate cancer is a negative prognosticator of overall survival [11]. Moreover, Armstrong et al. could show that the risk of death increased with each quartile of osseous tumor volume [11]. The total osseous tumor volume could therefore be employed to identify homogeneous groups of patients, which might benefit from altered therapy regimes. However, as visceral metastases are also frequently present in prostate cancer patients and are associated with a
poor outcome, a total tumor volume metric could be an even better prognosticator of overall survival in prostate cancer patients [1].

Other biomarkers have been employed to assess the disease extent and prognosis of prostate cancer patients. For example, the PCWG guideline recommends measuring prostate-specific antigen (PSA) blood levels to assess biochemical response to therapy [22]. However, the association of PSA levels and the total tumor volume might be hampered by androgen deprivation therapy and more importantly prostate cancer heterogeneity together with treatment-induced dedifferentiation [18, 23]. This is in line with the findings of the present study. PSA was not a statistically significant prognosticator of overall survival, which is indicating its limited value to monitor therapy response. Thus, therapeutic decisions in mCRPC should not be based on PSA but on imaging data and clinical symptoms.

Due to the detection of both bone and soft tissue metastases, PSMA PET derived total tumor volume might be superior to bone scan derived total tumor volume [24]. Therefore, several approaches have been proposed to quantify the total tumor volume in PSMA PET: Gafita et al. had proposed qPSMA, a software which segments all malignancy suspicious lesions in PSMA PET acquisitions based on a liver specific threshold [19]. Ferdinandus et al. had proposed a method in which all lesions were segmented by employing an SUV threshold of 3 [12]. Seifert et al. had proposed a two-step approach in which a liver specific threshold was employed for lesion selection and a regional threshold (50% of the local SUV_max) for lesion segmentation [13]. In the present study, the quantification approach of Seifert et al. was employed [13].

There are diverting reports on the prognostic value of PSMA PET derived total tumor volume in patients with end-stage prostate cancer who receive Lu-PSMA therapy: Ferdinandus et al. could show that the FDG PET derived total tumor volume and the bone scan derived tumor volume were negative prognosticators of survival; yet the PSMA PET derived tumor volume was not a statistically significant prognosticator in their study [12]. This finding seems counter intuitive, as greater tumor volume is generally linked with worse outcome. Seifert et al. could show that the tumor volume is a negative prognosticator of overall survival in a preliminary analysis [13]. Here, we corroborated these findings by broadening the patient collective and including patients from a second department. PSMA-TV was a statistically significant negative prognosticator of overall survival. In line with the findings from the bone scan tumor volume analyses, the PSMA-
TV parameter was superior to the lesion number as a prognosticator of overall survival in patients with end-stage prostate cancer.

It was shown previously that $SUV_{\text{mean}}$ is a positive prognosticator of survival for patients with end-stage prostate cancer receiving Lu-PSMA therapy [12, 15]. In line with the concept of theranostics, high $SUV_{\text{mean}}$ is associated with higher tumor doses of Lu-PSMA therapy and should therefore be linked to a favorable outcome [25]. Therefore, the integration of tumor volume and SUV to form a combined biomarker seems reasonable, which was done in analogy to FDG total lesion glycolysis by Seifert et al. and Gafita et al. [13, 19]. However, as the tumor volume is a negative prognosticator and SUV uptake a positive prognosticator, both metrics may

| Parameter                  | Threshold | Above threshold OS [95%CI] | Below threshold OS [95%CI] | $p$ Value |
|----------------------------|-----------|----------------------------|---------------------------|-----------|
| Lesion number              | 9         | NR [11.0–NR]; n = 16       | 11.1 [7.5–13.2]; n = 94   | 0.004     |
| PSMA-TV                    | 41.1      | NR [7.8–NR]; n = 19        | 11.2 [7.5–14.2]; n = 91   | 0.036     |
| PSMA-TLU                   | 495.2     | NR [7.9–NR]; n = 18        | 11.1 [7.5–13.2]; n = 92   | 0.015     |
| PSMA-TLQ                   | 4.1       | 23.5 [12.9–NR]; n = 26     | 9.9 [7.0–13.2]; n = 84    | 0.011     |
| Prostate-specific antigen  | 514       | 14.8 [11.4–25.5]; n = 77   | 7.2 [5.1–8.6]; n = 33     | 0.014     |
| Lactate dehydrogenase      | 316       | 15.6 [11.0–NR]; n = 54     | 7.5 [5.7–11.8]; n = 55    | 0.020     |

NR not available due to not reached median survival. CI confidence interval, PSMA-TV PSMA tumor volume, PSMA-TLU PSMA tumor volume multiplied by $SUV_{\text{mean}}$, PSMA-TLQ PSMA tumor volume divided by $SUV_{\text{mean}}$
antagonize in the PSMA-TLU biomarker. Therefore, a novel biomarker (PSMA-TLQ) was proposed by this study, which is the quotient of total tumor volume and \(SUV_{\text{mean}}\). As expected, PSMA-TLQ was a better prognosticator of survival compared with lesion number and even to PSMA-TV. Interestingly, PSMA-TLQ remained a significant prognosticator of overall survival, even if the regression was adjusted for the presence of visceral, bone, and lymph node metastases. Therefore, it might be warranted to evaluate PSMA-TLQ in future studies and determine if the weighting between tumor volume and \(SUV\) can be optimized.

The estimated overall survival of patients significantly decreased with increasing PSMA-TLQ. Interestingly, the overall survival between quintile 1, quintiles 2–4, and quintile 5 were statistically significant different. Quintiles 2 to 4 were pooled, as these were not adequately separating groups with distinct median overall survival, which was likely due to the limited sample size. Stratification of patients according to quintiles of a radiographic biomarker is in line with the findings of Armstrong et al. regarding the bone scan tumor volume [11]. Therefore, the PSMA-TLQ biomarker might be used to identify homogenous patient cohorts for treatment intensification.

PSMA-TLQ was a statistically significant prognosticator of overall survival; the metric integrates the tumor volume and \(SUV_{\text{mean}}\). As mentioned above, higher \(SUV_{\text{mean}}\) is generally associated with higher dose delivery through PSMA targeted therapy [25]. If more aggressive prostate cancer cell phenotypes evolve, the PSMA expression might decrease [26]. Because of that, FDG PET is sometimes performed in addition to PSMA PET, which helps to detect dedifferentiated metastases [12]. To date, it remains unclear if the favorable outcome of end-stage patients with a strong PSMA expression is due to higher dose delivery, lesser dedifferentiation, or a combination of both. Interestingly, high PSMA expression can likewise be a marker of aggressive tumor phenotypes. Especially in the primary staging of prostate cancer, strong PSMA expression is associated with higher Gleason scores [27]. However, the implications of in vivo PSMA tracer
uptake are poorly elucidated in a castration resistant and metastatic situation.

The present analysis had some limitations. The analysis was performed retrospectively and is therefore prone to selection biases. Alkaline phosphatase levels were not present for all patients. Moreover, the tumor volume was determined as whole-body metric and not in an organ-wise manner. As visceral metastases are associated with shorter overall survival time, future studies should quantify an organ system wise tumor volume. Additionally, the sample size was limited, which might hamper generalizability. However, to minimize those effects, a bicentric approach was chosen. No FDG PET was included in the analysis as it was not implemented in the clinical routine for the included patients. The volume of dedifferentiated tumor parts that could not adequately be captured by PSMA PET might have been correctly quantified by FDG PET. Therefore, future studies integrating the findings of FDG PET and PSMA PET are warranted. These studies should also evaluate PSMA-TV and PSMA-TLQ changes over time to establish both as response parameters.

**Conclusion**

PSMA tumor volume was a negative prognosticator of survival in patients treated with Lu-PSMA therapy. PSMA-TLQ, a metric integrating PSMA tumor volume and PET uptake, was a statistically independent prognosticator of survival in a multivariate analysis and might be a new PET based metric to prognosticate response to radioligand therapies. Future studies are warranted to corroborate these findings in end-stage prostate cancer patients treated with other systemic therapies.

**Acknowledgments** We thank Bernadette Riemann for the excellent support in reviewing the clinical follow-up data.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Compliance with ethical standards**

**Conflict of interest** KR has received consultant fees from Bayer and lectureship fees from Janssen Cilag, Amgen, AAA, and SIRTex. KR is a clinical consultant for ABX. The University of Muenster has received consulting fees from ABX Advanced Biochemical Compounds, Radeberg, Germany for KR. MB has received consultant and lectureship fees from Bayer, Janssen Cilag, Astellas, ABX, Sanofi, Eisai, EUSAPharm, Pfizer, BMS, MSD, AstraZeneca, Merck, Amgen, Novartis, Exelixis, and Roche. WPf is a consultant for Endocyte and BTG, and he received fees from RadioMedix and Bayer outside of the submitted work. BAH has had advisory roles for ABX, Astellas, Bayer, Bristol Myers Squibb, Janssen R&D, Lightpoint Medical, Inc., and Pfizer; has received research funding from Astellas, Bristol Myers Squibb, German Cancer Aid, German Research Foundation, and Janssen R&D; and has received compensation for travel from Astellas, AstraZeneca, and Janssen R&D.
Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. The retrospective analysis of the Muenster cohort was approved by the local ethics committee (No. 2016-585-F-S, Ethikkommission der Ärztekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität Münster). The retrospective analysis of the Essen cohort was approved by the local ethics committee (No. 19-8570-BO).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 2018;378:645–57.
2. Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, et al. German multicenter study investigating [177Lu]-PSMA-617 radioguided therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90.
3. Hofman MS, Violet J, Hicks RJ, Ferdinandi J, Ping Thang S, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825–33.
4. Seifert R, Kessel K, Schlack K, Weckesser M, Bögemann M, Rahbar K. Radioguided therapy using [177Lu]-PSMA-617 in mCRPC: a pre-VISION single-center analysis. Eur J Nucl Med Imaging. 2020;47(9):2106–12.
5. Hofman MS, Emmett L, Violet J, Zhang AY, Lawrence NJ, Stockler M, et al. TheraP: a randomized phase 2 trial of [177Lu]-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BIU Int. 2019;124:5–13.
6. Rahbar K, Bodei L, Morris MJ. Is the “VISION” of radioguided therapy for prostate cancer becoming reality? an overview of the phase III trial and the future for theranostics. J Nucl Med. 2019. https://doi.org/10.2967/jnumed.119.234054.
7. Ahmadzadehfar H, Rahbar K, Küpögü S, Bögemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioguided therapy with [177Lu]-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNNMI Res. 2015;5:114.
8. Hofman M, Emmett L, Violet JA, Lawrence NJ, Williams S, Stockler MR, et al. TheraP: a randomized phase II trial of [177Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37:TPS332. [Internet]. American Society of Clinical Oncology; Available from: https://doi.org/10.1200/JCO.2019.37.7_suppl.TPS332.
9. Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46.
10. Kyriakopoulos CE, Chen Y-H, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36:1080–7.
11. Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, Bjartell A, Widmark A, et al. Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4:944–51.
12. Ferdinandi J, Violet J, Sandhu S, Hicks RJ, Ravi Kumar AS, Ivran I, et al. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging. 2020;47:2322–7.
13. Seifert R, Herrmann K, Kleesiek J, Schaferas MA, Shah V, Xu Z, et al. Semi-automatically quantified tumor volume using Ga-68-PSMA-11-PET as biomarker for survival in patients with advanced prostate cancer. J Nucl Med. 2020. https://doi.org/10.2967/jnumed.120.242057 [Internet]. Available from: http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.120.242057.
14. Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czemin J, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-11 ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46:2536–44.
15. Seifert R, Seitzer K, Herrmann K, Kessel K, Schaferas M, Kleesiek J, et al. Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioguided therapy. Theranostics. 2020;10(17):7812–20.
16. Gafita A, Fendler WP, Hui W, Sandhu S, Weber M, Esfandiari R, et al. Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement: a multicenter retrospective study. Eur Urol. 2020;78(2):148–54.
17. Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016;41:522–8.
18. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruck D, et al. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate. 2003;54:249–57.
19. Gafita A, Bieth M, Krönke M, Tetteh G, Navarro F, Wang H, et al. qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using 68 Ga-PSMA11 PET/CT. J Nucl Med. 2019;60:1277–83.
20. R Core Team. R: a language and environment for statistical computing [Internet]. Vienna: R Foundation for Statistical Computing; 2018. Available from: http://www.R-project.org/.
21. Rothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal. 2003;43:121–37.
22. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402–18.
23. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36:2492–503.
24. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34:1652–9.

25. Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60:517–23.

26. Bakht MK, Derecichei I, Li Y, Ferraiuolo RM, Dunning M, Oh SW, et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer. 2019;26:131–46.

27. Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44:941–9.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.